ストックスクリーナーアプリを入手
4.63
2.89%
0.13
アフターアワーズ：
4.58
-0.05
-1.08%
前日終値:
$4.50
開ける：
$4.41
24時間の取引高:
1.27M
Relative Volume:
0.72
時価総額：
$437.30M
収益：
$829.00M
当期純損益:
$-399.90M
株価収益率:
-1.0728
EPS:
-4.3159
ネットキャッシュフロー:
$-23.20M
1週間 パフォーマンス:
+8.94%
1か月 パフォーマンス:
+21.20%
6か月 パフォーマンス:
-29.42%
1年 パフォーマンス:
-4.73%
1日の値動き範囲:
$4.39
$4.7089
1週間の範囲:
$4.22
$4.7089
52週間の値動き範囲:
$3.53
$8.59
Myriad Genetics Inc Stock (MYGN) Company Profile
名前
Myriad Genetics Inc
セクター
電話
801-584-3600
住所
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Compare MYGN vs TMO, DHR, IDXX, A, WAT
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
4.63 | 428.79M | 829.00M | -399.90M | -23.20M | -4.3159 |
TMO
Thermo Fisher Scientific Inc
|
469.35 | 172.66B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
178.97 | 125.40B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
541.31 | 44.34B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
126.67 | 35.89B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
357.20 | 34.90B | 3.77B | 449.25M | 240.68M | 7.8556 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-21 | ダウングレード | Scotiabank | Sector Outperform → Sector Perform |
| 2025-05-08 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2025-05-07 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-04-09 | ダウングレード | Guggenheim | Buy → Neutral |
| 2025-03-12 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2025-02-12 | 開始されました | Craig Hallum | Buy |
| 2024-12-10 | 開始されました | UBS | Neutral |
| 2024-12-09 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-09-19 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-08-28 | 開始されました | Wells Fargo | Overweight |
| 2024-06-27 | 開始されました | Scotiabank | Sector Outperform |
| 2024-06-03 | 再開されました | Jefferies | Underperform |
| 2024-05-08 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2023-12-21 | 再開されました | Piper Sandler | Neutral |
| 2023-12-19 | 開始されました | Wells Fargo | Equal Weight |
| 2023-12-14 | 開始されました | Guggenheim | Buy |
| 2023-12-13 | 開始されました | Wolfe Research | Outperform |
| 2023-07-05 | 再開されました | JP Morgan | Underweight |
| 2023-05-23 | アップグレード | Goldman | Sell → Buy |
| 2023-01-18 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2022-10-06 | 開始されました | Stephens | Equal-Weight |
| 2021-10-15 | 再開されました | Cowen | Market Perform |
| 2021-06-15 | 開始されました | Raymond James | Mkt Perform |
| 2021-06-03 | 開始されました | Goldman | Sell |
| 2019-09-26 | ダウングレード | BofA/Merrill | Neutral → Underperform |
| 2019-08-14 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2019-08-02 | アップグレード | BofA/Merrill | Underperform → Neutral |
| 2019-08-01 | アップグレード | Barclays | Underweight → Equal Weight |
| 2019-07-29 | ダウングレード | Needham | Strong Buy → Hold |
| 2019-07-09 | ダウングレード | Cowen | Outperform → Market Perform |
| 2019-03-12 | 繰り返されました | Needham | Strong Buy |
| 2019-01-03 | 開始されました | Needham | Strong Buy |
| 2018-11-30 | アップグレード | Goldman | Sell → Neutral |
| 2018-10-10 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2018-07-11 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2018-03-21 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2018-01-29 | 開始されました | Goldman | Sell |
| 2018-01-22 | 繰り返されました | Barclays | Equal Weight |
| 2018-01-05 | 開始されました | BTIG Research | Buy |
| 2017-10-02 | 再開されました | Leerink Partners | Mkt Perform |
| 2017-08-09 | 繰り返されました | Barclays | Equal Weight |
| 2017-02-08 | アップグレード | Ladenburg Thalmann | Sell → Neutral |
| 2017-01-18 | 開始されました | Deutsche Bank | Sell |
| 2016-10-10 | ダウングレード | Ladenburg Thalmann | Neutral → Sell |
すべてを表示
Myriad Genetics Inc (MYGN) 最新ニュース
Myriad Genetics expands cancer detection test availability - Investing.com
Myriad Genetics expands cancer detection test availability By Investing.com - Investing.com Canada
Myriad Genetics director Daniel Skovronsky resigns from board - Investing.com
Myriad widens cancer test access as breast study bolsters its case - Stock Titan
Myriad Genetics director Daniel Skovronsky resigns from board By Investing.com - Investing.com Canada
Form 8K Myriad Genetics Inc For: 23 June By Investing.com - Investing.com Canada
Board member Skovronsky exits Myriad Genetics (NASDAQ: MYGN) - Stock Titan
Myriad Genetics StockAnalyst views and sector comparison on a quiet news day - AD HOC NEWS
Ovarian Cancer Diagnostics Market Size to Reach USD 8.08 Billion by 2035 | SNS Insider - GlobeNewswire Inc.
Myriad Genetics Inc (MYGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Myriad Genetics Inc (MYGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Myriad Genetics Inc (MYGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Myriad Genetics Inc (MYGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Myriad Genetics Inc (MYGN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Myriad Genetics Inc (MYGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Myriad Genetics Inc (MYGN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Myriad Genetics Inc (MYGN) Institutional Confidence - TradingKey
Myriad Genetics (NASDAQ: MYGN) CEO adds 3,542 shares via employee stock purchase plan - Stock Titan
Executive at Myriad Genetics (MYGN) adds 5,000 shares via ESPP plan - Stock Titan
Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Average Rating of "Hold" from Analysts - MarketBeat
Insider Sell Alert: Rashmi Kumar Sells 15,000 Shares of Myriad G - GuruFocus
Myriad Genetics (MYGN) director sells 15,000 shares under 10b5-1 plan - Stock Titan
Should You Add Myriad Genetics Stock to Your Portfolio Right Now? - Yahoo! Finance Canada
[144] MYRIAD GENETICS INC SEC Filing - Stock Titan
Director at Myriad Genetics (MYGN) receives 59,701 restricted stock units - Stock Titan
Myriad Genetics (MYGN) director awarded 59,701 restricted stock units - Stock Titan
Myriad Genetics (MYGN) grants 59,701 RSUs to director Mark Davis - Stock Titan
[Form 4] MYRIAD GENETICS INC Insider Trading Activity - Stock Titan
Myriad Genetics (MYGN) director receives 59,701 restricted stock units in equity grant - Stock Titan
Myriad Genetics (NASDAQ: MYGN) director receives 59,701 restricted stock units - Stock Titan
Myriad Genetics (MYGN) grants 59,701 RSUs to board director Bisaro - Stock Titan
Myriad Genetics (NASDAQ: MYGN) director granted 59,701 restricted stock units in equity award - Stock Titan
Myriad Genetics (NASDAQ: MYGN) shareholders approve 2026 equity and purchase plans - Stock Titan
Myriad (MYGN) Up 7.1% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Myriad Genetics Inc Annual Shareholders Meeting Transcript - GuruFocus
Dr. Crystal Nelson Explains How Genetic Testing Is Transforming Mental Health Medication Treatment on YourUpdateTV - The Manila Times
Myriad Genetics (MYGN) CTO Raj Jampa receives 251,889 restricted stock units - Stock Titan
Myriad Genetics (MYGN) CTO Raj Jampa files initial Form 3 insider report - Stock Titan
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026 - TradingView
Myriad Genetics names Raj Jampa as chief technology officer - Investing.com UK
Myriad Genetics Names Raj Jampa as New Chief Technology Officer - The Globe and Mail
Press Release: Myriad Genetics Names Raj Jampa as New Chief Technology Officer - Moomoo
Statistics Show that Patients Want More Personalized Mental Health Care - KOIN.com
MYGN Stock Price, Quote & Chart | MYRIAD GENETICS INC (NASDAQ:MYGN) - ChartMill
Myriad Genetics, Inc. (MYGN) News, Articles, Events & Latest Updates - Stocktwits
Myriad Genetics Inc stock (US62855J1043): Prolaris AI launch lifts focus - AD HOC NEWS
Is MYGN Stock a Buy at 0.4x Sales? What Investors Should Weigh - The Globe and Mail
Myriad Genetics' Upcoming Prolaris + AI Test Debut May Lift Its Stock - Yahoo Finance
MYGN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Myriad Genetics’ Precise MRD Assay Data Presented at ASCO 2026 Shows Potential for Assessing Treatment Response and Monitoring Recurrence in Cancer Patients - geneonline.com
Myriad Genetics Highlights Data Demonstrating Broad Clinical Utility of Precise Mrd Assay At 2026 Asco Annual Meeting - marketscreener.com
Myriad Genetics Inc (MYGN) 財務データ
収益
当期純利益
現金流量
EPS
1.86%
0.64%
大文字化:
|
ボリューム (24 時間):